Clicky

VAXCYTE INC. DL -001(5VA)

Description: Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.


Keywords: Biotechnology Disease Vaccines Pneumonia Periodontitis Pneumococcal Conjugate Vaccine Pneumococcal Vaccine

Home Page: vaxcyte.com

825 Industrial Road
San Carlos, CA 94070
United States
Phone: 650 837 0111


Officers

Name Title
Mr. Grant E. Pickering M.B.A. Co-Founder, CEO & Director
Mr. Andrew L. Guggenhime M.B.A. President & CFO
Mr. James Wassil M.B.A., M.S. Executive VP & COO
Mr. Mikhail Eydelman J.D. Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Ashish Khanna M.B.A., Ph.D. Co-Founder
Dr. Jeff Fairman Ph.D. Co-Founder & VP of Research
Ms. Elvia Cowan Senior VP of Finance & Principal Accounting Officer
Ms. Janet Graesser Senior Vice President of Corporate Communications & Investor Relations
Ms. Whitney Jones Chief People Officer
Mr. Paul W. Sauer M.B.A. Senior Vice President of Process Development & Manufacturing

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.2427
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 254
Back to stocks